Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,984.00
Bid: 1,983.00
Ask: 1,984.00
Change: 25.00 (1.28%)
Spread: 1.00 (0.05%)
Open: 1,958.00
High: 1,988.00
Low: 1,950.00
Prev. Close: 1,984.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

15 Jan 2020 09:44

RNS Number : 8766Z
Hikma Pharmaceuticals Plc
15 January 2020
 

1.1 Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.

Name of the Issuer:

 

Hikma Pharmaceuticals PLC

2.

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.

Name of person discharging managerial responsibilities/director:

Said Darwazah, Mazen Darwazah and Ali Al-Husry

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Yes: Darhold Limited

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

Beneficial interest in Darhold Limited

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

EFG Bank

8.

State the nature of the transaction:

Pledge of 2,345,000 Ordinary Shares in support of a loan

9.

Number of shares, debentures or financial instruments relating to shares acquired:

None

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

11.

Number of shares, debentures or financial instruments relating to shares disposed:

None

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.

Price per share or value of transaction:

N/A

14.

Date and place of transaction:

Amman, 15 January 2020

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

60,000,000 - 24.76 per cent.

16.

Date issuer informed of transaction:

15 January 2020

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.

Date of grant

18.

Period during which or date on which exercisable

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

24.

Name of contact and telephone number for queries

 

Name of authorised official or issuer responsible for making notification

Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification: 15 January 2020

 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGCGDBGSBDGGU
Date   Source Headline
22nd Apr 20164:22 pmRNSDirector/PDMR Shareholding
20th Apr 20164:00 pmRNSDirector/PDMR Shareholding
19th Apr 20164:14 pmRNSDirector/PDMR Shareholding
19th Apr 201612:57 pmRNSDirector/PDMR Shareholding
12th Apr 201610:02 amRNSDirector/PDMR Shareholding
8th Apr 20167:00 amRNSPortfolio Update - VR315 US
8th Apr 20167:00 amRNSUpdate on ANDA for Generic Advair Diskus®
7th Apr 20164:08 pmRNSDirector/PDMR Shareholding
7th Apr 201611:41 amRNSAnnual Information Update
7th Apr 201610:54 amRNSAnnual Financial Report
6th Apr 20164:11 pmRNSBlocklisting Interim Review
5th Apr 20164:13 pmRNSDirector/PDMR Shareholding
31st Mar 20165:37 pmRNSDirector/PDMR Shareholding
29th Mar 20169:36 amRNSDirector/PDMR Shareholding
21st Mar 20162:54 pmRNSDirector/PDMR Shareholding
17th Mar 20163:25 pmRNSDirector/PDMR Shareholding
16th Mar 20167:00 amRNSFinal Results
3rd Mar 20169:25 amRNSNotice of Results
29th Feb 20162:01 pmRNSHolding(s) in Company
29th Feb 20161:59 pmRNSHolding(s) in Company
29th Feb 20161:47 pmRNSTotal Voting Rights
29th Feb 20161:46 pmRNSRoxane Acquisition Close
22nd Feb 20169:52 amRNSDirectorate Change
19th Feb 201612:55 pmRNSEGM Statement
11th Feb 201612:43 pmRNSHolding(s) in Company
11th Feb 201612:19 pmRNSCirc re. Roxane Acquisition
10th Feb 201610:38 amRNSHikma Analyst and Investor Call
10th Feb 20167:00 amRNSCirc re. Roxane Acquisition
22nd Jan 20162:04 pmRNSCirc re. Roxane Acquisition and EGM
7th Jan 201611:08 amRNSTotal Voting Rights
24th Dec 20157:52 amRNSShareholders' Agreement and Board Appointment
17th Dec 20159:38 amRNSTotal Voting Rights
3rd Dec 20159:30 amRNSDirector/PDMR Shareholding
25th Nov 20158:45 amRNSHikma announces sale of Ben Venue manufacturing
24th Nov 20157:00 amRNSHolding(s) in Company
18th Nov 20157:00 amRNSResolution to FDA Warning Letter
16th Nov 20153:04 pmRNSHolding(s) in Company
11th Nov 20154:16 pmRNSHolding(s) in Company
10th Nov 20152:43 pmRNSHolding(s) in Company
2nd Nov 20157:00 amRNSTrading Statement
22nd Oct 20157:00 amRNSBlock Listing of Share
19th Oct 201511:11 amRNSHolding(s) in Company
12th Oct 201510:25 amRNSBlocklisting Interim Review
8th Oct 20154:10 pmRNSTotal Voting Rights
18th Sep 20152:40 pmRNSAudit Tender
16th Sep 20154:08 pmRNSTotal Voting Rights
11th Sep 20153:47 pmRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSHikma agrees to acquire EIMC United Pharmaceutical
27th Aug 20154:02 pmRNSDirector/PDMR Shareholding
27th Aug 20153:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.